Cargando…
Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial
A Belgian ring trial for pan-TRK immunohistochemistry (IHC) staining was organised to harmonise pan-TRK IHC staining protocols and interpretation. As a reference method, the VENTANA pan-TRK Assay (clone EPR17341) on the Benchmark Ultra platform was selected. Six samples were selected: 2 negative, 2...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969564/ https://www.ncbi.nlm.nih.gov/pubmed/32915263 http://dx.doi.org/10.1007/s00428-020-02921-6 |
_version_ | 1783666250036019200 |
---|---|
author | De Winne, Koen Sorber, Laure Lambin, Suzan Siozopoulou, Vasiliki Beniuga, Gabriela Dedeurwaerdere, Franceska D’Haene, Nicky Habran, Lionel Libbrecht, Louis Van Huysse, Jacques Weynand, Birgit Wouters, Katrin Pauwels, Patrick Zwaenepoel, Karen |
author_facet | De Winne, Koen Sorber, Laure Lambin, Suzan Siozopoulou, Vasiliki Beniuga, Gabriela Dedeurwaerdere, Franceska D’Haene, Nicky Habran, Lionel Libbrecht, Louis Van Huysse, Jacques Weynand, Birgit Wouters, Katrin Pauwels, Patrick Zwaenepoel, Karen |
author_sort | De Winne, Koen |
collection | PubMed |
description | A Belgian ring trial for pan-TRK immunohistochemistry (IHC) staining was organised to harmonise pan-TRK IHC staining protocols and interpretation. As a reference method, the VENTANA pan-TRK Assay (clone EPR17341) on the Benchmark Ultra platform was selected. Six samples were selected: 2 negative, 2 fusion positive and 2 samples with wild-type endogenous TRK expression. Each participating laboratory stained the slides using their routine pan-TRK IHC and reported their results. In addition, they were asked to return one TRK-stained slide from each case. The coordinating lab evaluated these slides, compared them with the reference method and scored them. Two clones were used during the ring trial: A7H6R (Cell Signaling) and EPR17341 (Abcam/Ventana). Seven protocols achieved a sufficient performance mark, and three labs were advised to further optimise the protocol. Interpretation of pan-TRK IHC proved to be challenging in cases with physiological TRK expression. In addition, depending on the NTRK fusion partner, the staining can vary strongly in both intensity and staining pattern. Labs using the Ventana ready-to-use system based on the EPR17341 clone and using the recommended protocol settings scored best. However, given some small optimisation, all labs scored well on the technical staining and the succeeding evaluation. |
format | Online Article Text |
id | pubmed-7969564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-79695642021-04-05 Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial De Winne, Koen Sorber, Laure Lambin, Suzan Siozopoulou, Vasiliki Beniuga, Gabriela Dedeurwaerdere, Franceska D’Haene, Nicky Habran, Lionel Libbrecht, Louis Van Huysse, Jacques Weynand, Birgit Wouters, Katrin Pauwels, Patrick Zwaenepoel, Karen Virchows Arch Original Article A Belgian ring trial for pan-TRK immunohistochemistry (IHC) staining was organised to harmonise pan-TRK IHC staining protocols and interpretation. As a reference method, the VENTANA pan-TRK Assay (clone EPR17341) on the Benchmark Ultra platform was selected. Six samples were selected: 2 negative, 2 fusion positive and 2 samples with wild-type endogenous TRK expression. Each participating laboratory stained the slides using their routine pan-TRK IHC and reported their results. In addition, they were asked to return one TRK-stained slide from each case. The coordinating lab evaluated these slides, compared them with the reference method and scored them. Two clones were used during the ring trial: A7H6R (Cell Signaling) and EPR17341 (Abcam/Ventana). Seven protocols achieved a sufficient performance mark, and three labs were advised to further optimise the protocol. Interpretation of pan-TRK IHC proved to be challenging in cases with physiological TRK expression. In addition, depending on the NTRK fusion partner, the staining can vary strongly in both intensity and staining pattern. Labs using the Ventana ready-to-use system based on the EPR17341 clone and using the recommended protocol settings scored best. However, given some small optimisation, all labs scored well on the technical staining and the succeeding evaluation. Springer Berlin Heidelberg 2020-09-11 2021 /pmc/articles/PMC7969564/ /pubmed/32915263 http://dx.doi.org/10.1007/s00428-020-02921-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article De Winne, Koen Sorber, Laure Lambin, Suzan Siozopoulou, Vasiliki Beniuga, Gabriela Dedeurwaerdere, Franceska D’Haene, Nicky Habran, Lionel Libbrecht, Louis Van Huysse, Jacques Weynand, Birgit Wouters, Katrin Pauwels, Patrick Zwaenepoel, Karen Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial |
title | Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial |
title_full | Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial |
title_fullStr | Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial |
title_full_unstemmed | Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial |
title_short | Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial |
title_sort | immunohistochemistry as a screening tool for ntrk gene fusions: results of a first belgian ring trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969564/ https://www.ncbi.nlm.nih.gov/pubmed/32915263 http://dx.doi.org/10.1007/s00428-020-02921-6 |
work_keys_str_mv | AT dewinnekoen immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT sorberlaure immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT lambinsuzan immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT siozopoulouvasiliki immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT beniugagabriela immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT dedeurwaerderefranceska immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT dhaenenicky immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT habranlionel immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT libbrechtlouis immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT vanhuyssejacques immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT weynandbirgit immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT wouterskatrin immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT pauwelspatrick immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial AT zwaenepoelkaren immunohistochemistryasascreeningtoolforntrkgenefusionsresultsofafirstbelgianringtrial |